Skip to main content
Research:
Research
14 Jun 2021
5 minute read

Distribution and Supply Chain Models in the Cell & Gene Therapy Landscape

How are Cell and Gene therapies transforming patients' lives? What is their impact on the current and future curative treatment landscape? How should pharma manufacturing and other relevant stakeholders plan for a higher degree of operating model sophistication required for Cell and Gene therapies?

Distribution and Supply Chain Models in the Cell & Gene Therapy Landscape
Download PDF (5MB) View PDF

Cell and Gene therapies (CGT), including personalized medicines, have rapidly transformed the curative treatment landscape. The personalized nature of these therapies demand a greater degree of operating model sophistication. The complexity stems from a requirement for an end-to-end traceability of viable cells to manufacturing to bedside infusion, and long term follow-up. Further, the need to provide a greater degree of transparency of manufacturing processes to patients and healthcare professionals, including regulatory requirements, makes it critical to think through innovative operating model designs.

What is the focus of the Distributor Paper?In this paper, we will focus on the Cell and Gene therapy product flow, outline the hurdles and opportunities created within supply chain distribution flows, describe alternate distribution models expected in the CGT supply chain and explore the required capabilities.

The paper aims to answer questions such as:

  • What are the primary drivers facilitating the CGT operating model?
  • What differentiates CGT from traditional distribution models?
  • How will CGT change the way biopharma companies collaborate with logistic partners?
  • How do biopharma companies partner with distribution firms?
  • How are distributors innovating beyond their traditional role?

Did you find this useful?

Yes
No

Thanks for your feedback

Your feedback is important to us

To tell us what you think, please update your settings to accept analytics and performance cookies.

Need help updating cookies?

Key contacts

Lieven Comeyne

Lieven Comeyne

Partner | Global Life Sciences Supply Chain & Operations practice lead
+32 2 749 54 86
Richard Rahul Maria

Richard Rahul Maria

+ 32 2 800 29 95

Recommendations

Agile Data Quality Framework

Deloitte Belgium has developed a data quality framework specifically designed to assess the data risks and data health. The framework facilitates analysis and provides insights into the root causes of poor data quality. It also offers appropriate remediation recommendations to enhance data standardization activities. 
Research
10 minute read

Automation with intelligence

In Deloitte's automation survey, executives speak about the role of cloud, automation-as-a-service and the impact of COVID-19 on the progress made.
Research
5 minute read

The 2022 Chief Strategy Officer (CSO) Survey

Corporate strategists look to fuel growth amidst continued uncertainty
Research
5 minute read

Data governance | Deloitte Belgium

Apply the 10 design principles listed in Deloitte Belgium’s article at any stage of your data governance journey to successfully create value from your data.
Research
5 minute read